In short
Resmetirom, also known as MGL-3196, is an investigational drug being studied in clinical trials for its potential to treat Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) cirrhosis. These trials aim to evaluate the safety, tolerability, and effectiveness of Resmetirom in various patient populations, including those with severe renal impairment. The studies focus on assessing the drug's impact on liver-related outcomes, biomarkers, and overall patient health.
At a glance
- Drug Name
- Resmetirom (MGL-3196)
- Conditions Studied
- Non-Alcoholic Fatty Liver Disease (NAFLD), NASH Cirrhosis
- Administration
- Oral tablet, once daily
- Dosages
- 40 mg, 80 mg, 100 mg (varies by study)
- Study Durations
- 52 weeks to 3 years
- Primary Outcomes
- Safety, tolerability, liver-related clinical outcomes
- Secondary Outcomes
- Changes in liver fat, blood lipids, liver stiffness
- Special Populations
- NASH cirrhosis patients, severe renal impairment
- Measurement Tools
- MRI-PDFF, FibroScan, blood tests, MELD score
What is Resmetirom?
Resmetirom, also known by its alternative names MGL-3196 and Rezdiffra, is an investigational drug that is currently being studied for its potential in treating liver-related conditions. It is a medication taken orally in tablet form, which means it can be easily administered at home without the need for injections or hospital visits.
What Conditions Does Resmetirom Treat?
Resmetirom is primarily being investigated for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD). NAFLD is a condition where excess fat accumulates in the liver of people who drink little to no alcohol. In some cases, NAFLD can progress to a more severe form called Non-Alcoholic Steatohepatitis (NASH), which can lead to liver cirrhosis.
Specifically, Resmetirom is being studied for its potential to help patients with:
- NAFLD: The early stages of fatty liver disease
- NASH: A more severe form of fatty liver disease with inflammation
- NASH Cirrhosis: Advanced liver scarring resulting from NASH
How Does Resmetirom Work?
While the exact mechanism of action is not fully explained in the provided clinical trial data, Resmetirom is known to target certain aspects of liver function and fat metabolism. It appears to have effects on: Hepatic fat fraction: This refers to the amount of fat in the liver, which Resmetirom may help reduce Lipid levels: The drug may help lower LDL-C (often called "bad" cholesterol) and triglycerides in the blood Liver stiffness: Resmetirom might help improve liver elasticity, which is a measure of liver health
Clinical Trials and Research
Resmetirom is currently undergoing extensive clinical trials to evaluate its safety and effectiveness. Some key studies include:
- MAESTRO-NAFLD-1: A 52-week study evaluating the safety and effects of Resmetirom on various biomarkers in patients with NAFLD
- MAESTRO-NAFLD-OLE: An open-label extension study to further assess the long-term safety and effects of Resmetirom
- MAESTRO-NASH-OUTCOMES: A study focusing on the effects of Resmetirom on clinical outcomes in patients with well-compensated NASH cirrhosis
These trials are designed to measure various outcomes, including changes in liver fat, cholesterol levels, and the occurrence of liver-related events.
How is Resmetirom Administered?
Resmetirom is taken orally as a tablet, typically once daily in the morning. The dosage being studied varies across trials, with common doses including:
- 40 mg for some patients with NASH cirrhosis
- 80 mg daily
- 100 mg daily
The appropriate dosage may depend on the specific condition being treated and individual patient factors.
Potential Side Effects and Safety
A primary focus of the ongoing clinical trials is to evaluate the safety and tolerability of Resmetirom. While specific side effects are not detailed in the provided information, the studies are closely monitoring:
- The incidence of adverse events
- Changes in various biomarkers that could indicate safety concerns
- Long-term safety over extended periods of use
It's important to note that as an investigational drug, the full safety profile of Resmetirom is still being established through these clinical trials.
Future Research and Potential
Ongoing research is exploring the potential of Resmetirom beyond its primary focus on NAFLD and NASH. Some areas of investigation include:
- Effects on liver-related outcomes: Studying how Resmetirom might impact the progression of liver disease and related complications
- Cardiovascular effects: Investigating potential benefits on heart health, given its effects on cholesterol levels
- Use in special populations: Studying how the drug behaves in patients with other conditions, such as severe renal impairment
These ongoing studies will help determine the full potential of Resmetirom and identify the patients who might benefit most from this treatment.